deoxyuridine has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y; Li, L; Li, R; Wu, J; Zhan, H; Zhong, C; Zhou, C | 1 |
| Benhadji, KA; Callies, S; Cohen, RB; Faivre, SJ; Horn, CL; Myrand, SP; Olszanski, AJ; Ouyang, H; Raymond, E; Riess, H; Wang, X; Weigang-Köhler, K; Wickremsinhe, ER | 1 |
1 trial(s) available for deoxyuridine and Disease Exacerbation
| Article | Year |
|---|---|
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2015 |
1 other study(ies) available for deoxyuridine and Disease Exacerbation
| Article | Year |
|---|---|
MYC-activated lncRNA HNF1A-AS1 overexpression facilitates glioma progression via cooperating with miR-32-5p/SOX4 axis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Deoxyuridine; Disease Progression; DNA Nucleotidylexotransferase; Flow Cytometry; Gene Silencing; Glioma; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Proteins; Proto-Oncogene Proteins c-myc; RNA, Long Noncoding; SOXC Transcription Factors; Transcription Factors | 2020 |